Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 15/20 | 1.00 |
| ▸ | ITK | Q08881 | 2/20 | 0.46 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 3/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL166896 | 1.00 | BTK (1.00) | BTKITKTNK2EGFRERBB2 | |
| SCHEMBL19986670 | 0.93 | BTK (0.86) | BTKEGFRERBB2 | |
| SCHEMBL16788366 | 0.93 | BTK (0.86) | BTKEGFRERBB2 | |
| SCHEMBL122280 | 0.91 | BTK (1.00) | BTKITKTNK2EGFR | |
| SCHEMBL124181 | 0.90 | BTK (0.82) | BTKITKTNK2EGFRERBB2 | |
| SCHEMBL124552 | 0.89 | BTK (0.80) | BTKTNK2EGFR | |
| SCHEMBL174843 | 0.89 | BTK (0.80) | BTKTNK2EGFR | |
| SCHEMBL16440887 | 0.89 | BTK (0.80) | BTKITKEGFRERBB2 | |
| SCHEMBL122566 | 0.88 | BTK (0.94) | BTKITKTNK2EGFR | |
| SCHEMBL19736258 | 0.88 | BTK (0.78) | BTKITKTNK2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180078555-A1 | METHODS OF TREATING AND PREVENTING GRAFT VERSUS HOST DISEASE | PHARMACYCLICS, INC. | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180078555-A1 | METHODS OF TREATING AND PREVENTING GRAFT VERSUS HOST DISEASE | BLK, DCK, CILK1 | BTK 8/4885ITK 28/4885TNK2 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.